TY - JOUR
T1 - Conformational ensemble of the TNF-derived peptide solnatide in solution
AU - Martin-Malpartida, Pau
AU - Arrastia-Casado, Silvia
AU - Farrera-Sinfreu, Josep
AU - Lucas, Rudolf
AU - Fischer, Hendrik
AU - Fischer, Bernhard
AU - Eaton, Douglas C.
AU - Tzotzos, Susan
AU - Macias, Maria J.
N1 - Funding Information:
P.M.M. and M.J.M. gratefully acknowledge institutional funding from the CERCA Programme of the Government of Catalonia , IRB Barcelona , the BBVA Foundation , the AGAUR and the SGR Excellent Research Group recognition programme (2017 SGR 50) and the Spanish Ministry of Science and Education through the Centres of Excellence Severo Ochoa Award.
Funding Information:
The study was supported, in part, by the EU special H2020 program “Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic” (call ID: SC1-PHE-CORONAVIRUS-2020) under the grant number 101003595, and by the Austrian Research Promotion Agency (FFG), Grant No.880862. RL and DCE were supported by R01 grant HL138410 from the NIH/NHLBI, DCE is supported by U.S. NIH grant DK-110409. M.J.M. is an ICREA Program Investigator.
Funding Information:
P.M.M. and M.J.M. gratefully acknowledge institutional funding from the CERCA Programme of the Government of Catalonia, IRB Barcelona, the BBVA Foundation, the AGAUR and the SGR Excellent Research Group recognition programme (2017 SGR 50) and the Spanish Ministry of Science and Education through the Centres of Excellence Severo Ochoa Award. The study was supported, in part, by the EU special H2020 program ?Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic? (call ID: SC1-PHE-CORONAVIRUS-2020) under the grant number 101003595, and by the Austrian Research Promotion Agency (FFG), Grant No.880862. RL and DCE were supported by R01 grant HL138410 from the NIH/NHLBI, DCE is supported by U.S. NIH grant DK-110409. M.J.M. is an ICREA Program Investigator.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/1
Y1 - 2022/1
N2 - Tumor necrosis factor (TNF) is a homotrimer that has two spatially distinct binding regions, three lectin-like domains (LLD) at the TIP of the protein and three basolaterally located receptor-binding sites, the latter of which are responsible for the inflammatory and cell death-inducing properties of the cytokine. Solnatide (a.k.a. TIP peptide, AP301) is a 17-mer cyclic peptide that mimics the LLD of human TNF which activates the amiloride-sensitive epithelial sodium channel (ENaC) and, as such, recapitulates the capacity of TNF to enhance alveolar fluid clearance, as demonstrated in numerous preclinical studies. TNF and solnatide interact with glycoproteins and these interactions are necessary for their trypanolytic and ENaC-activating activities. In view of the crucial role of ENaC in lung liquid clearance, solnatide is currently being evaluated as a novel therapeutic agent to treat pulmonary edema in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), as well as severe COVID-19 patients with ARDS. To facilitate the description of the functional properties of solnatide in detail, as well as to further target-docking studies, we have analyzed its folding properties by NMR. In solution, solnatide populates a set of conformations characterized by a small hydrophobic core and two electrostatically charged poles. Using the structural information determined here and also that available for the ENaC protein, we propose a model to describe solnatide interaction with the C-terminal domain of the ENaCα subunit. This model may serve to guide future experiments to validate specific interactions with ENaCα and the design of new solnatide analogs with unexplored functionalities.
AB - Tumor necrosis factor (TNF) is a homotrimer that has two spatially distinct binding regions, three lectin-like domains (LLD) at the TIP of the protein and three basolaterally located receptor-binding sites, the latter of which are responsible for the inflammatory and cell death-inducing properties of the cytokine. Solnatide (a.k.a. TIP peptide, AP301) is a 17-mer cyclic peptide that mimics the LLD of human TNF which activates the amiloride-sensitive epithelial sodium channel (ENaC) and, as such, recapitulates the capacity of TNF to enhance alveolar fluid clearance, as demonstrated in numerous preclinical studies. TNF and solnatide interact with glycoproteins and these interactions are necessary for their trypanolytic and ENaC-activating activities. In view of the crucial role of ENaC in lung liquid clearance, solnatide is currently being evaluated as a novel therapeutic agent to treat pulmonary edema in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), as well as severe COVID-19 patients with ARDS. To facilitate the description of the functional properties of solnatide in detail, as well as to further target-docking studies, we have analyzed its folding properties by NMR. In solution, solnatide populates a set of conformations characterized by a small hydrophobic core and two electrostatically charged poles. Using the structural information determined here and also that available for the ENaC protein, we propose a model to describe solnatide interaction with the C-terminal domain of the ENaCα subunit. This model may serve to guide future experiments to validate specific interactions with ENaCα and the design of new solnatide analogs with unexplored functionalities.
KW - AP301 peptide
KW - AlphaFold applications
KW - Alveolar fluid clearance
KW - Amiloride-sensitive epithelial sodium channel
KW - Amphipathic helix
KW - ENaC
KW - Peptide NMR
KW - Pulmonary edema
KW - Solnatide structure
KW - TIP peptide
KW - Tumor necrosis factor
UR - http://www.scopus.com/inward/record.url?scp=85129361036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129361036&partnerID=8YFLogxK
U2 - 10.1016/j.csbj.2022.04.031
DO - 10.1016/j.csbj.2022.04.031
M3 - Article
AN - SCOPUS:85129361036
SN - 2001-0370
VL - 20
SP - 2082
EP - 2090
JO - Computational and Structural Biotechnology Journal
JF - Computational and Structural Biotechnology Journal
ER -